Manufacturer:
Biocon Biologics
Route of Administration:
Subcutaneous
Site of Care:
Outpatient
Website:
phone:
1-833-695-2623
Approved Indication:
to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
Therapeutic Area:
- Oncology